Safety and efficacy of lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra in patients with metastatic castration-resistant prostate cancer (mCRPC)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Lutetium-177 zadavotide guraxetan (Primary) ; Radium 223 chloride (Primary)
Indications Prostate cancer
Focus Adverse reactions
Acronyms RALU study

01 Apr 2023 Results (n=49) assessing safety and survival outcomes with 177Lu-PSMA in patients treated with prior 223Ra, published in the Journal of Nuclear Medicine.
13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
30 Aug 2022 According to a Bayer media release, data from the trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com